JP3469258B2 - Agent for improving renal function - Google Patents
Agent for improving renal functionInfo
- Publication number
- JP3469258B2 JP3469258B2 JP29775492A JP29775492A JP3469258B2 JP 3469258 B2 JP3469258 B2 JP 3469258B2 JP 29775492 A JP29775492 A JP 29775492A JP 29775492 A JP29775492 A JP 29775492A JP 3469258 B2 JP3469258 B2 JP 3469258B2
- Authority
- JP
- Japan
- Prior art keywords
- tea polyphenols
- present
- tea
- agent
- mesangial cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pyrane Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
【０００１】[0001]
【産業上の利用分野】本発明は、天然植物に含まれる特
定の成分を有効成分として含有する糸球体腎炎や糖尿病
性腎症の進行に関与しているメサンギウム細胞の増殖を
特異的に阻害する作用を有するメサンギウム細胞増殖に
より生じる障害の改善剤に関する。TECHNICAL FIELD The present invention specifically inhibits the proliferation of mesangial cells involved in the progression of glomerulonephritis and diabetic nephropathy, which contain specific components contained in natural plants as active ingredients. The present invention relates to an agent for improving a disorder caused by proliferation of mesangial cells, which has an action.
【０００２】[0002]
【従来の技術】腎疾患の中で、糸球体濾過機能が低下し
て、慢性腎不全へと進行するような糸球体腎炎や糖尿病
性腎症は、組織学的，病理学的にメサンギウム細胞の増
殖に起因するものと特徴づけられている。つまり、メサ
ンギウム細胞の収縮，弛緩を介して糸球体毛細血管の血
行動態に影響を及ぼし、糸球体濾過を調節しているとい
う生理機能が同細胞の増殖により障害されることを意味
している。慢性腎不全の原疾患の70〜80％は慢性に経過
する糸球体腎炎や糖尿病性腎症であることから、メサン
ギウム細胞の増殖や調節機構の解明は、非常に重要であ
る。以上の観点から、メサンギウム細胞に対し抑制効果
を有する因子の研究が、近年盛んに行われているが、未
だ有効な物質が見い出されていないのが現状である。2. Description of the Related Art Among renal diseases, glomerulonephritis and diabetic nephropathy, in which the glomerular filtration function is deteriorated and progresses to chronic renal failure, are histologically and pathologically identified as mesangial cell Characterized as being due to proliferation. That is, it means that the physiological function of regulating glomerular filtration is affected by proliferation of mesangial cells, which affects the hemodynamics of glomerular capillaries through contraction and relaxation of the mesangial cells. Since 70 to 80% of the primary diseases of chronic renal failure are chronic glomerulonephritis and diabetic nephropathy, elucidation of mesangial cell proliferation and regulatory mechanism is very important. From the above viewpoints, research on factors having an inhibitory effect on mesangial cells has been actively conducted in recent years, but the present situation is that effective substances have not yet been found.
【０００３】[0003]
【発明が解決しようとする課題】本発明は、副作用の心
配のない古くから飲用等に用いられている天然物に含ま
れ、糸球体濾過調節を障害しうるメサンギウム細胞の増
殖を特異的に阻害する作用を有するメサンギウム細胞増
殖により生じる障害の改善剤を提供することを目的とす
る。DISCLOSURE OF THE INVENTION The present invention is contained in a natural product which has been used for drinking since ancient times without fear of side effects, and specifically inhibits the proliferation of mesangial cells which may impair glomerular filtration regulation. It is an object of the present invention to provide a remedy for a disorder caused by proliferation of mesangial cells, which has the effect of
【０００４】[0004]
【課題を解決するための手段】本発明は、メサンギウム
細胞の増殖を特異的に阻害する組成物であって、没食子
酸，（＋）−カテキン，（＋）−ガロカテキン，（−）
−エピカテキン，（−）−エピガロカテキン，（−）−
エピカテキンガレート，（−）−ガロカテキンガレー
ト，（−）−エピガロカテキンガレートおよびこれらの
二量体，三量体等の茶より抽出された茶ポリフェノール
類を有効成分として，含有することを特徴とするメサン
ギウム細胞増殖により生じる障害の改善剤が提供され
る。本発明は、茶ポリフェノール類を有効成分とするメ
サンギウム細胞増殖により生じる障害の改善剤である。
本発明において、茶ポリフェノール類とは、没食子酸，
（＋）−カテキン，（＋）−ガロカテキン，（−）−エ
ピカテキン，（−）−エピガロカテキン，（−）−エピ
カテキンガレート，（−）−ガロカテキンガレート，
（−）−エピガロカテキンガレートおよびこれらの二量
体，三量体等を指す。The present invention is a composition for specifically inhibiting the proliferation of mesangial cells, which comprises gallic acid, (+)-catechin, (+)-gallocatechin, (-).
-Epicatechin, (-)-epigallocatechin, (-)-
It is characterized by containing tea polyphenols extracted from tea such as epicatechin gallate, (−)-gallocatechin gallate, (−)-epigallocatechin gallate and their dimers and trimers as active ingredients. An agent for improving disorders caused by mesangial cell proliferation is provided. The present invention is an agent for improving disorders caused by proliferation of mesangial cells, which contains tea polyphenols as an active ingredient.
In the present invention, tea polyphenols include gallic acid,
(+)-Catechin, (+)-gallocatechin, (-)-epicatechin, (-)-epigallocatechin, (-)-epicatechin gallate, (-)-gallocatechin gallate,
(-)-Epigallocatechin gallate and dimers, trimers and the like thereof.
【０００５】本発明に使用し得る茶ポリフェノール類
は、例えば、茶葉より抽出することができるが、その抽
出方法については、特に限定されず、茶ポリフェノール
類が高濃度で抽出される方法であることが望ましい。原
料として使用する茶葉は、生葉から仕上げ茶（乾燥茶）
まで、通常の製茶工程のいずれの段階のものでも良く、
かつ発酵の程度に関係なく不発酵茶，半発酵茶，発酵茶
いずれでも使用できる。これら化合物の調製法は、例え
ば本発明者らが先に出願した特許（特開昭６４−９０１
２４号及び特開平１−２６５０２３号）に開示されてい
る。The tea polyphenols that can be used in the present invention can be extracted from, for example, tea leaves, but the extraction method is not particularly limited, and the tea polyphenols can be extracted at a high concentration. Is desirable. The tea leaves used as raw materials range from fresh leaves to finished tea (dry tea).
Up to any stage of the normal tea making process,
In addition, unfermented tea, semi-fermented tea or fermented tea can be used regardless of the degree of fermentation. The method for preparing these compounds is described, for example, in the patent previously filed by the present inventors (Japanese Patent Laid-Open No. 64-901).
No. 24 and Japanese Patent Laid-Open No. 1-265023).
【０００６】次に、本発明の有効成分である茶ポリフェ
ノール類が、メサンギウム細胞の増殖抑制作用を有する
こと及び安全性について試験例を挙げて説明する。
試験例１．メサンギウム細胞の増殖抑制作用
（１）メサンギウム細胞の培養
ａ．ヒト腎生検によって得た腎皮質を、リン酸緩衝生理
食塩水中で約１mm3 に細切する。
ｂ．細片を金属メッシュ（No.60 ，No.120，No.280の順
番，飯田製作所製）上でシリコン製ヘラでふるい分け
し、No.280のメッシュ上の糸球体を採取する。
ｃ．20％ＦＣＳ（アルモア社製），100 μｇ／ｍｌスト
レプトマイシン（明治製菓社製），100 Ｕ／ｍｌペニシ
リン（明治製菓社製）を含むＲＰＭＩ1640（日水製薬社
製）の培養液に糸球体を浮遊させ、培養ディッシュ（直
径60mm，コーニング社製）にばらまき、37℃，５％ＣＯ
2 の条件下で培養する。
ｄ．培養７日目に培養液を交換し、さらに７日間培養す
る。培養14日目に糸球体周囲に増殖した細胞を培養ディ
ッシュから0.25％トリプシン（ディフコ社製），0.02％
ＥＤＴＡ（同仁化学社製）で剥離し、培養フラスコ（コ
ーニング社製）に継代する。さらに、７日間培養して、
培養フラスコ底面に増殖していることが確認できた細胞
を使用する。[0006] Next, the tea polyphenols, which are the active ingredients of the present invention, will be described with reference to test examples with regard to the effect of suppressing the proliferation of mesangial cells and their safety. Test Example 1. Growth-inhibitory effect of mesangial cells (1) Culture of mesangial cells a. The renal cortex obtained by human renal biopsy is minced into approximately 1 mm 3 in phosphate buffered saline. b. The strips are sieved on a metal mesh (No. 60, No. 120, No. 280, Iida Seisakusho) with a silicon spatula to collect the glomeruli on the No. 280 mesh. c. Float the glomerulus in RPMI1640 (Nissui Pharmaceutical Co., Ltd.) culture solution containing 20% FCS (Almore Co., Ltd.), 100 μg / ml streptomycin (Meiji Seika Co., Ltd.), 100 U / ml penicillin (Meiji Seika Co., Ltd.) And spread on a culture dish (60 mm in diameter, Corning), 37 ° C, 5% CO
Incubate under the conditions of 2 . d. The culture medium is exchanged on the 7th day of culture, and the culture is continued for 7 days. Cells grown around the glomerulus on day 14 of culture were 0.25% trypsin (Difco), 0.02% from the culture dish.
Peel off with EDTA (Dojindo Co., Ltd.) and subculture to a culture flask (Corning Co.). In addition, after culturing for 7 days,
Use cells that have been confirmed to grow on the bottom of the culture flask.
【０００７】（２）培養メサンギウム細胞増殖の測定
ａ．メサンギウム細胞を104 個／ｍｌ（あるいは105 個
／ｍｌ）の濃度にし、96穴平底培養用プレート（コーニ
ング 25860）に100 μｌ接種する。培養液は20％ＦＣＳ
添加Ｄ−ＶａｌＭＥＭを使用する。
ｂ．24時間培養してメサンギウム細胞がプレートに付着
しているのを確認後、培養液をオートサッカーで吸い取
り、ハンク氏溶液で一度洗浄する。洗浄後ＦＣＳ
（−），Ｄ−ＶａｌＭＥＭを200 μｌ添加し、48時間培
養する。
ｃ．48時間培養後、ハンク氏溶液で一度洗浄し、８％
ＦＣＳ添加Ｄ−ＶａｌＭＥＭで適当な濃度に希釈したサ
ンプルの200 μｌを使用する。
ｄ．24時間培養し、培養終了の６時間前にチミジン（Ｔ
ＲＫ686 ，Methyl− 3Ｈ−thymidine ，アマシャム社
製）を１μＣｉ／ｗｅｌｌ添加する。
ｅ．24時間培養後、培養液をトリプシン＋ＥＤＴＡ液に
置換し、メサンギウム細胞を剥がす。実体顕微鏡でメサ
ンギウム細胞が円形になったのを確認後、セルハーベス
ターを用い、細胞をガラスフィルター上に付着させる。
ｆ．シンチレーション カウンターで測定する。(2) Measurement of proliferation of cultured mesangial cells a. The mesangial cells are made to have a concentration of 10 4 cells / ml (or 10 5 cells / ml), and 100 μl of the mesangial cells are inoculated on a 96-well flat bottom culture plate (Corning 25860). The culture solution is 20% FCS
Use added D-Val MEM. b. After culturing for 24 hours and confirming that the mesangial cells are attached to the plate, the culture solution is sucked with autosucker and washed once with Hank's solution. FCS after cleaning
200 μl of (-), D-ValMEM is added, and the mixture is cultured for 48 hours. c. After culturing for 48 hours, wash once with Hank's solution, 8%
Use 200 μl of sample diluted to the appropriate concentration with FCS-supplemented D-ValMEM. d. Cultivate for 24 hours and thymidine (T
RK686, Methyl- 3 H-thymidine, Amersham) is added 1 [mu] Ci / well. e. After culturing for 24 hours, the culture solution is replaced with trypsin + EDTA solution, and mesangial cells are removed. After confirming that the mesangial cells have become circular with a stereoscopic microscope, the cells are attached on a glass filter using a cell harvester. f. Measure with a scintillation counter.
【０００８】[0008]
【図１】[Figure 1]
【０００９】図１に示すように、茶ポリフェノール類6.
25μｇ／ｍｌからメサンギウム細胞の増殖に対する抑制
作用が認められ、その作用は添加量の増加とともに増強
した。上記、結果に示すように、本発明の有効成分であ
る茶ポリフェノール類は、メサンギウム細胞の増殖抑制
し、腎機能の改善に有効であると考えられる。As shown in FIG. 1, tea polyphenols 6.
From 25 μg / ml, an inhibitory effect on the proliferation of mesangial cells was observed, and the effect was enhanced with an increase in the amount added. As shown in the above results, it is considered that the tea polyphenols, which are the active ingredients of the present invention, are effective in suppressing the growth of mesangial cells and improving the renal function.
【００１０】試験例２．急性毒性試験
ｄｄｙ系マウス雌雄各10匹に、生理食塩水に懸濁した本
発明の有効成分である茶ポリフェノール類を恒温（23±
１℃），恒湿（55±５％ＲＨ）の条件で経口投与し、急
性毒性試験を行なった結果、5,000 ｍｇ／ｋｇの投与で
は、死亡例はなかった。Test Example 2. Acute toxicity test Each of 10 male and female ddy mice was kept at a constant temperature (23 ±) with tea polyphenols as an active ingredient of the present invention suspended in physiological saline.
Oral administration was carried out under the conditions of 1 ° C.) and constant humidity (55 ± 5% RH), and an acute toxicity test was conducted. As a result, no death occurred at the administration of 5,000 mg / kg.
【００１１】試験例３．変異原性試験
サルモネラ（ネズミチフス菌）におけるヒスチジン要求
性から非要求性への復帰変異を指標とするＡｍｅｓテス
トを行った。検定菌として、サルモネラ・チフィムリウ
ム ＴＡ100 及びサルモネラ・チフィムリウム ＴＡ98
を用い、直接試験と代謝活性化試験を実施した。その結
果、本発明の有効成分である茶ポリフェノール類は、直
接試験、代謝活性化試験における変異コロニーの増加は
認められず、変異原性を有しない（陰性）と判定され
た。Test Example 3. Mutagenicity test An Ames test was carried out using a histidine-requiring reversion mutation in Salmonella (Salmonella typhimurium) as an index. As test bacteria, Salmonella typhimurium TA100 and Salmonella typhimurium TA98
Was used to carry out a direct test and a metabolic activation test. As a result, it was determined that the tea polyphenols, which are the active ingredients of the present invention, did not show mutagenicity (negative) because no increase in mutant colonies was observed in the direct test and the metabolic activation test.
【００１２】上記結果に示すように、本発明に用いる有
効成分である茶ポリフェノール類は毒性は認められず、
極めて安全性が高く、効果の優れた腎機能改善用剤の提
供が可能となったといえる。次に本発明を実施例により
詳しく説明する。経口的には錠剤，カプセル剤，顆粒
剤，細粒剤，散剤，液剤等としても摂取が可能である。
最適摂取量は、年齢，体重を考慮する必要があるが、通
常100 ｍｇから10ｇを１日数回に分けて摂取するのが好
ましい。経口的に摂取する以外に、注射，外用液剤，軟
コウ，座剤等の方法での投与も可能であり、非経口的な
投与の場合、投与量は１ｍｇ〜250 ｍｇを一日何回かに
分けて投与するのが望ましい。製剤化する場合の原材料
及び製造方法は、通常のものと何ら変わることなく製造
できる。As shown in the above results, the tea polyphenols, which are the active ingredients used in the present invention, showed no toxicity.
It can be said that it has become possible to provide an agent for improving renal function, which is extremely safe and has excellent effects. Next, the present invention will be described in detail with reference to Examples. It can be taken orally as tablets, capsules, granules, fine granules, powders and liquids.
Although it is necessary to consider the age and body weight for the optimum intake, it is usually preferable to take 100 mg to 10 g divided into several times a day. In addition to oral ingestion, it can be administered by injection, topical solution, soft koh, suppository, etc. In the case of parenteral administration, the dosage is 1 mg to 250 mg several times a day. It is desirable to administer in divided doses. The raw materials and the manufacturing method for formulation can be manufactured without any change from usual ones.
【００１３】[0013]
実施例１
噴霧乾燥乳糖 １８８ ｇ
コーンスターチ １８．８ ｇ
ポリビニルピロリドン ３．２ ｇ
茶ポリフェノール類 ３０ ｇ
計 ２４０ ｇ
上記処方に従って、〜を均一に混合し、ゼラチンカ
プセルに各々、混合物400 ｍｇを充填した。このカプセ
ル１個には、本発明の有効成分である茶ポリフェノール
類が50ｍｇ含有されている。Example 1 Spray-dried lactose 188 g Corn starch 18.8 g Polyvinylpyrrolidone 3.2 g Tea polyphenols 30 g Total 240 g According to the above formulation, ~ were uniformly mixed, and gelatin capsules were each filled with 400 mg of the mixture. One capsule contains 50 mg of tea polyphenols, which is the active ingredient of the present invention.
【００１４】実施例２
コーンスターチ １９ ｍｇ
結晶セルロース ３０ ｍｇ
ステアリン酸マグネシウム １ ｍｇ
乳糖 ８０ ｍｇ
茶ポリフェノール類 ２０ ｍｇ
収量 １５０ ｍｇ
上記処方に従って、〜を均一に混合した後、圧縮成
型し、１錠150 ｍｇの錠剤とする。この錠剤には、本発
明の有効成分である茶ポリフェノール類が20ｍｇ含有さ
れている。Example 2 Corn Starch 19 mg Crystalline Cellulose 30 mg Magnesium Stearate 1 mg Lactose 80 mg Tea Polyphenols 20 mg Yield 150 mg According to the above formulation, the ingredients (1) and (2) were uniformly mixed, and then compression-molded. Use tablets. This tablet contains 20 mg of tea polyphenols, which is the active ingredient of the present invention.
【００１５】実施例３
砂糖 ３５０ ｇ
ソルビトール ２００ ｇ
パラオキシ安息香酸メチル ０．２ ｇ
パラオキシ安息香酸プロピル ０．１５ ｇ
クエン酸ナトリウム ８ ｇ
クエン酸 １．２ ｇ
香料 少量
茶ポリフェノール類 ２ ｇ
精製水 ４３８ ｇ
収量 １０００ ｇ
上記処方に従って、〜を溶解混合し、シロップ液と
する。このシロップ液50ｇには、本発明の有効成分であ
る茶ポリフェノール類が1000ｍｇ含有されている。Example 3 Sugar 350 g Sorbitol 200 g Methyl paraoxybenzoate 0.2 g Propyl paraoxybenzoate 0.15 g Sodium citrate 8 g Citric acid 1.2 g Fragrance Tea polyphenols 2 g Purified water 438 g Yield 1000 g According to the above formulation, are dissolved and mixed to prepare a syrup solution. 50 g of this syrup solution contains 1000 mg of tea polyphenols, which is the active ingredient of the present invention.
【００１６】また、本発明の有効成分である茶ポリフェ
ノール類は保健用食品等、例えば、キャンディー，キャ
ラメル，チョコレート，ゼリー，アイスクリーム，ヨー
グルト，チューインガム，焼菓子，もち，パン，生菓子
などの菓子類，コーヒー，茶，ジュース，乳飲料，アル
コール飲料等の飲料類，ふりかけ，佃煮，惣菜，ドレッ
シング，マヨネーズ，醤油，ソース，ケチャップ，みそ
汁，スープ，米飯類に添加し摂取することができる。The tea polyphenols which are the active ingredients of the present invention are health foods and the like, for example, confectionery such as candy, caramel, chocolate, jelly, ice cream, yogurt, chewing gum, baked confectionery, glutinous bread, fresh confectionery and the like. , Drinks such as coffee, tea, juice, milk drinks, alcoholic drinks, sprinkles, tsukudani, side dish, dressing, mayonnaise, soy sauce, sauce, ketchup, miso soup, soup, and rice can be ingested.
【００１７】実施例４
砂糖 ４０ ｇ
水あめ ２５ ｇ
水 ２５ ｍｌ
香料 少量
茶ポリフェノール類 ２ ｇ
収量 ６０ ｇ（出来上がり）
上記処方に従って，，を加熱して完全に溶解す
る。これをボーメ43度位まで煮つめていったん濾過し、
更に真空鍋で煮つめ、冷却し，を混合し充分練り上
げて、約70℃に冷却して型に入れる。このキャンディー
３ｇに本発明の有効成分である茶ポリフェノール類が10
0 ｍｇ含有されている。Example 4 Sugar 40 g Water starch syrup 25 g Water 25 ml Flavor Small amount Tea polyphenols 2 g Yield 60 g (Finished) According to the above formulation, is completely dissolved by heating. This is boiled to about 43 degrees and filtered once,
Boil in a vacuum pan, cool, mix and knead thoroughly, cool to about 70 ° C and put in a mold. 10 g of the tea polyphenols which is the active ingredient of the present invention is added to 3 g of this candy.
Contains 0 mg.
【００１８】実施例５
寒天 １２ ｇ
砂糖 ５００ ｇ
水あめ ３００ ｇ
水 ５００ ｍｌ
香料・洋酒 少量
茶ポリフェノール類 ９．５ ｇ
収量９５０ ｇ（出来上がり）
上記処方に従って、をに入れ、加熱溶解後、，
を順次添加しながら加熱する。103 ℃まで煮詰め、，
，を添加し冷却、凝固させる。適当な大きさに切断
する。この寒天ゼリー20ｇに本発明の有効成分である茶
ポリフェノール類が200 ｍｇ含有されている。Example 5 Agar 12 g Sugar 500 g Water candy 300 g Water 500 ml Perfume / Western sake Small amount Tea polyphenols 9.5 g Yield 950 g (finished)
Are added in sequence and heated. Boil down to 103 ℃,
, Is added to cool and solidify. Cut into appropriate size. 20 g of this agar jelly contains 200 mg of tea polyphenols which is an active ingredient of the present invention.
【００１９】実施例６
薄力粉 ３００ ｇ
砂糖 １５０ ｇ
バター ３００ ｇ
香料 少量
茶ポリフェノール類 ７．２ ｇ
収量 ７２０ ｇ（出来上がり）
上記処方に従って、を泡立て、を混合したを少量
ずつ加える。次にを均質に混合し、を適宜添加す
る。混和した生地は、冷蔵庫で冷却後厚さを一定に延ば
し、型抜きをする。焼きあげは180 〜200 ℃で７〜10分
間行なう。このクッキー10ｇに本発明の有効成分である
茶ポリフェノール類が100 ｍｇ含有されている。Example 6 Soft flour 300 g Sugar 150 g Butter 300 g Flavor Small amount Tea polyphenols 7.2 g Yield 720 g (finished) Next, are mixed homogeneously, and is added appropriately. After the mixed dough is cooled in a refrigerator, the thickness of the mixed dough is uniformly extended and the dough is die-cut. Bake at 180-200 ° C for 7-10 minutes. 10 g of this cookie contains 100 mg of tea polyphenols which is an active ingredient of the present invention.
【００２０】[0020]
【発明の効果】本発明によれば、副作用等の心配のない
古くから用いられている天然物である茶に含まれ、メサ
ンギウム細胞増殖により生じる障害の改善剤を大量に供
給することが可能であり、産業上極めて有用であると考
えられる。INDUSTRIAL APPLICABILITY According to the present invention, it is possible to supply a large amount of a remedy for a disorder caused by the proliferation of mesangial cells, which is contained in tea, which is a natural product that has been used for a long time without fear of side effects. Yes, it is considered to be extremely useful in industry.
【００２１】[0021]
【図１】第１図は、茶ポリフェノール類による、メサン
ギウム細胞の増殖抑制の成績を示したものである。FIG. 1 shows the results of suppressing the growth of mesangial cells by tea polyphenols.
フロントページの続き (51)Int.Cl.7 識別記号 ＦＩ // Ｃ０７Ｄ 311/62 Ｃ０７Ｄ 311/62 (72)発明者 金 武祚 三重県四日市市赤堀新町９番５号 太陽 化学株式会社内 (56)参考文献 特開 平６−16549（ＪＰ，Ａ) 特開 平４−26624（ＪＰ，Ａ) (58)調査した分野(Int.Cl.7，ＤＢ名) A61K 31/00 - 31/80 C07D 311/62 ＣＡ（ＳＴＮ) ＪＩＣＳＴファイル（ＪＯＩＳ) ＭＥＤＬＩＮＥ（ＳＴＮ) ＲＥＧＩＳＴＲＹ（ＳＴＮ)Continuation of front page (51) Int.Cl. 7 Identification code FI // C07D 311/62 C07D 311/62 (72) Inventor Kim Takehisa 9-5 Akahori Shinmachi, Yokkaichi-shi, Mie Prefecture Taiyo Kagaku Co., Ltd. (56 ) Reference JP-A-6-16549 (JP, A) JP-A-4-26624 (JP, A) (58) Fields investigated (Int.Cl. 7 , DB name) A61K 31/00-31/80 C07D 311/62 CA (STN) JISST file (JOIS) MEDLINE (STN) REGISTRY (STN)
Claims (2)
を有効成分とする、メサンギウム細胞増殖により生じる
障害の改善剤。1. An agent for improving a disorder caused by mesangial cell proliferation, which comprises a tea extract containing tea polyphenols as an active ingredient.
−カテキン、（＋）−ガロカテキン、（−）−エピカテ
キン、（−）−エピガロカテキン、（−）−ガロカテキ
ンガレート、（−）−エピガロカテキンガレート及びこ
れらの２量体、３量体より選ばれる１種又は２種以上で
ある請求項１記載のメサンギウム細胞増殖により生じる
障害の改善剤。2. The tea polyphenols are gallic acid, (+)
-Catechin, (+)-gallocatechin, (-)-epicatechin, (-)-epigallocatechin, (-)-gallocatechin gallate, (-)-epigallocatechin gallate and their dimers, trimers The agent for ameliorating disorders caused by mesangial cell proliferation according to claim 1, which is one or more selected from the group consisting of:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP29775492A JP3469258B2 (en) | 1992-10-09 | 1992-10-09 | Agent for improving renal function |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP29775492A JP3469258B2 (en) | 1992-10-09 | 1992-10-09 | Agent for improving renal function |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH06122626A JPH06122626A (en) | 1994-05-06 |
| JP3469258B2 true JP3469258B2 (en) | 2003-11-25 |
Family
ID=17850745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP29775492A Expired - Fee Related JP3469258B2 (en) | 1992-10-09 | 1992-10-09 | Agent for improving renal function |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3469258B2 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2294878A (en) * | 1994-11-14 | 1996-05-15 | Joan Louise Hibberd | Antiviral tea compositions |
| WO2003011339A1 (en) * | 2001-07-30 | 2003-02-13 | Dsm Ip Assets B.V. | Composition for epigallocatechin gallate |
| CA2569986A1 (en) * | 2004-06-14 | 2005-12-29 | Mars, Incorporated | Compositions and methods of use of dimer digallates |
| JP2006052191A (en) * | 2004-08-16 | 2006-02-23 | Taiyo Kagaku Co Ltd | Composition for preventing, ameliorating or treating diabetes |
| WO2006082643A1 (en) * | 2005-02-03 | 2006-08-10 | Taiyo Kagaku Co., Ltd. | Preventive, relieving or therapeutic composition for diabetes mellitus and/or diabetic nephropathy |
| WO2007020917A1 (en) * | 2005-08-18 | 2007-02-22 | The University Of Tokushima | Agent for enhancing and prolonging utrophin production and processed food comprising the same |
| CN101507760B (en) * | 2009-03-13 | 2013-03-27 | 四川省中医药科学院 | Medicine composite for treating kidney disease |
| CN108324843A (en) * | 2018-05-17 | 2018-07-27 | 重庆跃龙生物制药有限公司 | Chinese medicine composition and preparation method thereof for treating nephrosis |
-
1992
- 1992-10-09 JP JP29775492A patent/JP3469258B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPH06122626A (en) | 1994-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69919287T2 (en) | Ethyl acetate extract of indigo plant | |
| KR101651907B1 (en) | Composition for Prevention or Treatment of Obesity Comprising Tenebrio molitor larva extract or Tenebrio molitor larva suspension | |
| KR101668845B1 (en) | A pharmaceutical composition for preventing or treating bone diseases comprising Dendropanax morbifera extract | |
| EP0930019A2 (en) | Composition for treating obesity and foods and drinks containing the same | |
| JPH09143070A (en) | Inhibitory agent for lipase and lowering agent for triglyceride in blood | |
| KR20120128579A (en) | Pharmaceutical composition for prevention or treatment of atopic dermatitis comprising the extract Daphne genkwa, fraction of thereof or compound isolated therefrom as an active ingredient | |
| JP3469258B2 (en) | Agent for improving renal function | |
| WO2006112366A1 (en) | Lipopexia inhibitor and food or beverage | |
| JP4496127B2 (en) | Herbal extract mixture and preventive or therapeutic agent for osteoporosis | |
| JP2006022099A (en) | Pharmaceutical composition for preventing and treating periodontal disease containing extract of panax notoginseng(burk.) f. h. chen as active ingredient | |
| KR101491771B1 (en) | Preparing method for protaetia brevitarsis suspension and anti-obesity composition containing the same | |
| JP4949272B2 (en) | Mixed herbal extract of eringi, goka and sesame root, and composition for preventing and treating periodontal disease comprising the same as an active ingredient | |
| KR102158134B1 (en) | Antibacterial composition comprising an extract of schisandra chinesis | |
| KR20150092400A (en) | Bread comprising the extract of Cirsium setidens or Aster scaber for protection of brain neuronal cells and method of preparing the same | |
| JP4426674B2 (en) | Bone resorption inhibitor | |
| JP7271158B2 (en) | TRPA1 Activating Composition | |
| KR20160118551A (en) | Pharmaceutical composition for preventing or treating obesity comprising extract of persicaria perfoliata | |
| JP6739730B2 (en) | Pharmaceutical composition for promoting skin and bone activation and process for producing the same | |
| KR101862135B1 (en) | Novel diynoic acid compound and pharmaceutical composition for preventing or treating bone diseases comprising the same | |
| KR101693632B1 (en) | Composition for promoting hair growth comprising extract of Disporum sessile as an effective component | |
| JP2007246449A (en) | Lipolysis promoter and food, drink and feed each containing the same | |
| JP2649296B2 (en) | Composition for reducing uremic substances | |
| KR20190103665A (en) | Food composition for improving or preventing obesity containing extract of saururus chinensis | |
| KR102471629B1 (en) | Composition for preventing or treating inflammatory diseases comprising extracts of Acorus gramineus and Dendropanax morbifera | |
| KR102255000B1 (en) | Composition for preventing, improving or treating bone disease comprising Mentha arvensis extract as effective component |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080905 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090905 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090905 Year of fee payment: 6 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090905 Year of fee payment: 6 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100905 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100905 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110905 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120905 Year of fee payment: 9 |
|
| LAPS | Cancellation because of no payment of annual fees |